What is HIV-associated lipodystrophy?

What the research literature says

HIV-associated lipodystrophy emerged as a clinically-significant complication of HIV antiretroviral therapy (ART) in the late 1990s. The condition involves dysregulated adipose-tissue distribution: subcutaneous fat loss in the face, extremities, and buttocks (lipoatrophy) combined with visceral adipose accumulation (lipohypertrophy) in the abdomen and trunk. The metabolic consequences include insulin resistance, dyslipidemia, and increased cardiovascular risk.

Tesamorelin is FDA-approved for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The Falutz NEJM pivotal trial documented significant reductions in visceral adipose tissue with daily tesamorelin treatment (PMID 18057338). Long-term safety and continued-efficacy extension data was published in the Falutz long-term safety report (PMID 18690162). The pooled phase 3 analysis consolidated efficacy and safety findings (PMID 20554713). The Spooner pharmacotherapy review covers the clinical-pharmacology framework (PMID 22298602).

The mechanistic framework: tesamorelin engages the GHRH receptor on pituitary somatotroph cells, driving endogenous GH release and downstream IGF-1 axis activation. The GH-axis activation drives lipolysis in visceral adipose depots, producing the visceral-fat-reduction effect that anchors the clinical indication.

Why this matters in research context

HIV-associated lipodystrophy matters in peptide-research contexts as the clinical condition that anchors tesamorelin’s regulatory approval and clinical-development framework. Researchers studying tesamorelin pharmacology should understand the underlying clinical context — the visceral-adipose-reduction endpoint and the patient population — when interpreting protocol-design considerations.

Related compounds

• Tesamorelin 10mg — the approved-indication compound

Related research questions

• Is tesamorelin FDA approved?
• What is the typical tesamorelin dose?

References

1. Falutz J et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med 2007;357(23):2359-2370. [PMID 18057338]
2. Falutz J et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS 2008;22(14):1719-1728. [PMID 18690162]
3. Falutz J et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis. J Clin Endocrinol Metab 2010;95(9):4291-4304. [PMID 20554713]
4. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Ann Pharmacother 2012;46(2):240-247. [PMID 22298602]